Corcept Therapeutics Incorporated
$ 43.96
0.14%
16 Apr - close price
- Market Cap 4,676,201,000 USD
- Current Price $ 43.96
- High / Low $ 44.30 / 43.20
- Stock P/E 53.61
- Book Value 6.11
- EPS 0.82
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.15 %
- 52 Week High 91.00
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$67.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-04 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0.2 | 0.16 | 0.29 | 0.1693 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 | 0.14 |
| Estimated EPS | 0.254 | 0.13 | 0.1864 | 0.1425 | 0.4233 | 0.28 | 0.23 | 0.22 | 0.26 | 0.22 | 0.15 | 0.19 |
| Surprise | -0.054 | 0.03 | 0.1036 | 0.0268 | -0.1633 | 0.13 | 0.09 | 0.03 | 0.02 | 0.06 | 0.1 | -0.05 |
| Surprise Percentage | -21.2598% | 23.0769% | 55.5794% | 18.807% | -38.5778% | 46.4286% | 39.1304% | 13.6364% | 7.6923% | 27.2727% | 66.6667% | -26.3158% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-04-17 12:40:37
The Gross Law Firm has issued a shareholder alert for Corcept Therapeutics Incorporated (NASDAQ: CORT), urging investors who purchased shares during the class period of October 30, 2020, to December 23, 2023, to contact the firm. The alert concerns allegations that Corcept made false statements or concealed information regarding the adequacy of its relacorilant program assessment, especially concerning FDA concerns about its GRACE study design and potential approval issues. Shareholders have until April 21, 2026, to seek lead plaintiff appointment in the class action lawsuit.
2026-04-16 15:40:37
The Law Offices of Frank R. Cruz is urging shareholders of Corcept Therapeutics Incorporated (CORT) who experienced losses to contact them regarding a securities fraud class action lawsuit. The lawsuit stems from an FDA Complete Response Letter declining approval for Corcept's drug relacorilant, causing a significant drop in stock price. The deadline for investors to participate as a lead plaintiff is April 21, 2026.
2026-04-16 14:39:38
ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in Corcept Therapeutics (NasdaqCM: CORT) to file lead plaintiff applications by April 21, 2026, in a securities class action lawsuit. The lawsuit alleges that Corcept and its executives misrepresented the likelihood of FDA approval for their drug relacorilant, leading to a significant stock price drop after the FDA issued a Complete Response Letter on December 31, 2025. Investors who purchased shares between October 31, 2024, and December 30, 2025, are affected.
2026-04-15 21:10:03
The Rosen Law Firm is encouraging purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to join a class action lawsuit. The deadline to serve as lead plaintiff is April 21, 2026. The lawsuit alleges that Corcept misrepresented the clinical trial support for its relacorilant drug, leading to investor damages.
2026-04-15 19:10:03
Hagens Berman has issued an investor notice for Corcept Therapeutics (CORT), urging investors with significant losses to join a class action lawsuit by the April 21, 2026, lead plaintiff deadline. The lawsuit alleges that Corcept concealed FDA warnings about its drug relacorilant's data deficiency, leading to a 50% stock price drop after the FDA issued a Complete Response Letter. Investors who bought CORT stock between October 31, 2024, and December 30, 2025, are encouraged to submit their losses.
2026-04-15 17:10:03
Glancy Prongay Wolke & Rotter LLP is reminding investors of Corcept Therapeutics Incorporated (CORT) about an April 21, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges securities fraud, stemming from the FDA's decision to decline approval for Corcept's drug relacorilant due to concerns about its effectiveness, leading to a significant drop in the company's stock price. Investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, and suffered losses are encouraged to contact the firm.
